SMTL ID : 5gjg.1

Crystal structure of human TAK1/TAB1 fusion protein in complex with ligand 4

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.61 Å

Oligo State

monomer

Ligands

1 x 6V5: N-(2-isopropoxy-4-(4-methylpiperazine-1-carbonyl)phenyl)-2-(3-(phenylcarbamoyl)phenyl)thiazole-4-carboxamide(Non-covalent)

6V5.1: 19 residues within 4Å: Chain A: E.15, V.17, G.18, F.22, V.25, A.36, K.38, V.65, M.79, E.80, Y.81, A.82, E.83, G.85, S.86, L.138, C.149, D.150, F.151 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:V.17, A:F.22, A:F.22, A:V.25, A:Y.81, A:F.151 Hydrogen bonds: A:A.82, A:D.150 Salt bridges: A:E.15

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Muraoka, T. et al., Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD). Chem.Pharm.Bull. (2016)

Release Date

2016-11-16

Peptides

TAK1 kinase - TAB1 chimera fusion protein: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

TAK1 kinase - TAB1 chimera fusion protein

Related Entries With Identical Sequence